Search clinical trials for: L19IL2 L19TNF

Total 27 results

Philogen S.p.A.

Recruiting

Neoadjuvant L19IL2/L19TNF- Pivotal Study (Pivotal)

Malignant Melanoma

Italy, France, Germany, Poland
Philogen S.p.A.

Completed

Intratumoral Administration of L19IL2/L19TNF

Malignant Melanoma, Skin

Italy
Philogen S.p.A.

Recruiting

L19IL2/L19TNF in Skin Cancer Patients (IntriNSiC)

Kaposi Sarcoma | Merkel Cell Carcinoma | BCC - Basal Cell Carcinoma | SCC - Squamous Cell Carcinoma | Keratoacanthoma of Skin | Malignant Adnexal Tumors of the Skin (MATS) | Tumors From Cutaneous T-cell Lymphoma (CTCL)

Spain, France, Italy
Philogen S.p.A.

Recruiting

Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients (DUNCAN)

Carcinoma, Basal Cell | Carcinoma, Cutaneous Squamous Cell

Germany, Poland, Switzerland
Philogen S.p.A.
Merck Sharp & Dohme LLC

Active, not recruiting

Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients (INTACT/MeRCI)

Melanoma Stage IV | Melanoma Stage III

United States
Philogen S.p.A.
Syneos Health

Completed

A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours

Advanced Solid Tumours

Italy, Germany
Philogen S.p.A.

Completed

Intratumoral Application of L19IL2 in Patients With Malignant Melanoma

Malignant Melanoma

Austria, Germany
Philogen S.p.A.

Completed

Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse (GLIOMOON)

Glioma of Brain

Switzerland
Philogen S.p.A.
Eudax S.r.l.; InnoPharma Inc.

Completed

L19TNFα in Patients With Advanced Solid Tumors

Colorectal Cancer | Solid Tumors

Italy
Philogen S.p.A.

Active, not recruiting

A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma

Metastatic Melanoma Stage IV

Italy, Germany
Philogen S.p.A.
Eudax S.r.l.

Terminated

Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma

Metastatic Melanoma

Switzerland, Italy, Austria, Germany
Philogen S.p.A.

Recruiting

A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression (GLIOSTAR)

Glioblastoma

France, Germany, Italy, Switzerland
Philogen S.p.A.

Withdrawn

Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Progression (GLIOASTRA)

Glioblastoma
Philogen S.p.A.
Boehringer Ingelheim

Completed

Trial to Find and Investigate a Safe Dose of F16IL2 and BI 836858 in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation (PHIBI)

Acute Myeloid Leukemia (AML) Relapse

Germany
Philogen S.p.A.

Not yet recruiting

A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence (GLIOSTELLA)

Glioblastoma
Philogen S.p.A.

Recruiting

Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma (GLIOSUN)

Glioblastoma

Switzerland
Philogen S.p.A.

Recruiting

Efficacy and Safety of L19TNF in Previously Treated Patients With Advanced Stage or Metastatic Soft-tissue Sarcoma (FLASH)

Soft Tissue Sarcoma

France, Spain, Germany, Italy, Poland
Philogen S.p.A.

Active, not recruiting

Dose Finding Study of L19TNF and Doxorubicin in Patients With STS (DOXO75)

Soft Tissue Sarcoma

United States
Philogen S.p.A.

Recruiting

A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma (FIBROSARC)

Soft Tissue Sarcoma

Spain, Germany, France, Italy, Poland
Philogen S.p.A.

Recruiting

Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA) (FIBROSARC US)

Leiomyosarcoma

United States
Philogen S.p.A.

Completed

L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours

Advanced Solid Tumors Amenable to Anthracycline Therapy | Sarcoma, Breast Cancer, Lung Carcinomas, and Gynecological Cancer Amenable to Anthracycline Therapy

Germany, Italy
Philogen S.p.A.

Terminated

Combination Therapy of L19IL2 and Gemcitabine in Advanced Pancreatic Cancer Patients

Pancreatic Cancer Patients Diagnosed With Locally Advanced or Metastatic Pancreatic Cancer Not Amenable to Curative Surgical Resection

Italy, Germany
Philogen S.p.A.

Active, not recruiting

F16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung Cancer (Nivokin)

Non-small Cell Lung Cancer (NSCLC)

Switzerland
Philogen S.p.A.

Completed

Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients

Breast Cancer | Solid Tumor | Metastatic Melanoma | Non-small Cell Lung Cancer (NSCLC)

Italy
Philogen S.p.A.

Terminated

A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

Acute Myeloid Leukemia, Relapsed, Adult

Germany
Philogen S.p.A.

Terminated

Combination Therapy of F16IL2 and Doxorubicin in Solid Tumour Patients

Breast Cancer | Advanced Solid Tumor

Italy
Philogen S.p.A.
Immatics Biotechnologies GmbH

Terminated

F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma

Merkel Cell Carcinoma

Germany, Austria, Denmark, France, Spain, United Kingdom

3

Subscribe